Introduction
The fifth international Innovators in Urology meeting was held in June this year in Amsterdam, The Netherlands. A total of 46 delegates from 18 countries participated in what the delegates, faculty, and indeed all participants acknowledged as the most successful Innovators meeting yet.
The programme, designed by the experienced faculty (listed below), pulled different elements of clinical urology and career research science to offer an educational event unlike any other international meeting in the field. Highlights of the meeting included research poster critique sessions, journal analysis, and practical workshops. The standard of the poster presentations, their scientific content and the feedback sessions, were all exceptional. The related abstracts collated here include: prostate cancer's molecular biology and mechanisms, the diagnosis and treatment of the disease and epidemiological risk and prognosis factors.
The research of these innovative clinical urologists, oncologists, radiologists, and research scientists is detailed within this supplement. This innovative work is contributing greatly to the increasing pace in which we understand the disease.
On behalf of both the delegates and the faculty members, I would like to thank AstraZeneca, for their generous and ongoing support of this highly regarded programme, which continues to provide valuable insights into the optimum diagnosis and management of prostate cancer.
I look forward to the opportunity to meet again next year in Vancouver, Canada, 
